Well, well ... TexasDude ... come on in and pull up a chair.
The weather's fine here. This is a little known company which
has restructured last year and retargeted at bringing it's product
to market on it's own hook, after getting the marketing rights back
from Baxter, who ignored the product pretty much it appears.
The product is a Protien-A column, brand name "Prosorba", which
differentially bonds immune factors from blood plasma passed
through the column. The company holds several patents on the device.
If you look at the price history, you see it's stable as a rock, trending slowly upward with pre-earnings ramps. Analysts have
been coming online throughout the early part of this year ... small
private firms.
There are two good reports on the company:
Gruss and Sons -- (212) 952 1220
Evolution Capital -- (415) 989-3525, Kellie Seringer
These may be ordered from the company.
My prognostication is that we will trend up fairly stably with
the following milestones (beware, all my hallucination):
- ~ 4 area in July/August based on the FDA filing
- ~ 4-5 based on first clinical adoptions
- ~ 5-6 based on partnering/licensing with strong service partner
- upward based on revenues
One could plan to stay the long-haul, play the spikes around news, or both.
Very glad you stopped by ... your contributions would be very valuable.
(43 and counting, eh?) |
